Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
29.5M
-
Shares change
-
+88.4K
-
Total reported value, excl. options
-
$448M
-
Value change
-
+$4.13M
-
Put/Call ratio
-
1.64
-
Number of buys
-
65
-
Number of sells
-
-29
-
Price
-
$15.16
Significant Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q2 2020
142 filings reported holding AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share as of Q2 2020.
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.5M shares
.
Largest 10 shareholders include ORACLE INVESTMENT MANAGEMENT INC (4.07M shares), BlackRock Inc. (2.23M shares), Birchview Capital, LP (2.19M shares), AXA (2.04M shares), CREDIT SUISSE AG/ (1.78M shares), VANGUARD GROUP INC (1.51M shares), FMR LLC (1.46M shares), GRIFFIN ASSET MANAGEMENT, INC. (1.39M shares), CANNELL PETER B & CO INC (1.12M shares), and ArrowMark Colorado Holdings LLC (981K shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.